SCHEMBL5482098

SCHEMBL5482098

Cc1c[nH]c2c3c(ccc12)C(c1ccc(NS(C)(=O)=O)cc1)(c1ccc(NS(C)(=O)=O)cc1)C(=O)N3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
CNR1 P21554 1/20 0.39
GPR35 Q9HC97 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
KAT2B Q92831 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
KEAP1 Q14145 1/20 0.32
IKBKB O14920 2/20 0.32
CHUK O15111 2/20 0.32
PGR P06401 1/20 0.32
TDP2 O95551 1/20 0.32
KIF11 P52732 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482300 0.83 SMN1; SMN2 (0.52) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5486236 0.82 CNR1 (0.43) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5488447 0.80 CNR1 (0.41) HTTCNR1GPR35GPR55KDM4E
SCHEMBL5475383 0.76 MAPT (0.52) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5485549 0.76 KIF11 (0.40) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5480073 0.75 MET (0.44) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5484218 0.72 KIF11 (0.42) HTTCNR1GPR35GPR55KAT2B
SCHEMBL5478650 0.71 KIF11 (0.38) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5482310 0.66 SMN1; SMN2 (0.38) HTTSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5482451 0.66 SMN1; SMN2 (0.38) HTTSMN1; SMN2KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 HTT 1880/4885CNR1 973/4885GPR35 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.